Latest news
Silexion Therapeutics (NASDAQ: SLXN) files S-1 for best-efforts unit sale - Stock TitanStock Titan · Fri, 07 Aug 2026 22:52:53 GMTSilexion's SIL204 Alters Three Immune Pathways in Cancer Cells - Stock TitanStock Titan · Tue, 04 Aug 2026 13:15:00 GMTSilexion Therapeutics restores Nasdaq audit committee compliance with new appointment - TradingViewTradingView · Mon, 03 Aug 2026 13:33:01 GMTBiomotion Sciences Ordinary Shares (NASDAQ: SLXN) Stock Price, News & Analysis - KalkineKalkine · Fri, 31 Jul 2026 13:25:35 GMTAmnon Peled resigns from Silexion Therapeutics board effective Aug 1, 2026 - TradingViewTradingView · Fri, 31 Jul 2026 07:00:00 GMTSilexion Therapeutics Successfully Initiates Phase 2/3 - GlobeNewswireGlobeNewswire · Wed, 29 Jul 2026 11:00:00 GMT